Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 5 Gene copy number variation results from aCGH on seven sample pairs

From: Assessment of DNA methylation profiling and copy number variation as indications of clonal relationship in ipsilateral and contralateral breast cancers to distinguish recurrent breast cancer from a second primary tumour

Sample Loss of chromosome Gain of chromosome Recurrent/De novo Note
Ipsilateral 2 First tumour    Likely to be de novo  
Second tumour 2p, 3p (partial), 7q, 8q, 10p (partial), 19p
Ipsilateral 6 First tumour 3p (partial) 17q (partial) Likely to be recurrent The second tumour still retains the variation of the primary tumour, especially gain of 17q12 (Her2)
Second tumour 3p (partial), 4q, 8p, 9p, 10p, 11q, 13, 18 1q (partial), 12p, 14p, 17q (partial), 19p
Ipsilateral 11 First tumour   5q (partial), 8q (partial), 17q (partial) Recurrent Whole genome variation of primary and second tumour overlaid exactly
Second tumour   5q (partial), 8q (partial), 17q (partial)
Ipsilateral 12 First tumour 6q, 11q, 12q, 13 1q, 11p (partial), 12p, 12q (partial), 19 Likely to be recurrent Similar overall patterns in chromosome 11, 12 and 19
Second tumour 2q (partial), 3p (partial), 4, 6q, 7q (partial), 11q, 12q, 13 1q, 11p (partial), 12p, 12q (partial), 15, 19
Contralateral 3 First tumour 6q, 11q, 18 1q, 11p, 17q (partial) Likely to be de novo  
Second tumour 6q, 16q, 22 1q, 16p, Xq
Contralateral 10 First tumour 3p 6p, 8q Likely to be recurrent Similar overall patterns, especially in chromosome 8, 21 and 22
Second tumour   6p, 8q
Contralateral 13 First tumour   3p (partial), 8q, 11q (partial) Likely to be recurrent  
Second tumour   3p (partial), 8q, 11q (partial)